Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
In Sil ChoiMihong ChoiJu Hyun LeeJee Hyun KimKoung Jin SuhJi Yun LeeBeodeul KangJi-Won KimSe-Hyun KimJin Won KimJeong-Ok LeeYu Jung KimSoo-Mee BangJong Seok LeeKeun-Wook LeePublished in: PloS one (2018)
In patients with MGC receiving third-line chemotherapy, TF1T3 was the only significant factor associated with OS. The sequence of using taxane and irinotecan as subsequent therapy after first-line failure was not shown to impact survival outcome.